Production (Stage)
Tiziana Life Sciences Ltd
TLSA
$1.58
$0.2115.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.57M | 9.48M | 8.40M | 9.13M | 9.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.79M | 15.80M | 15.80M | 16.89M | 17.98M |
| Operating Income | -15.79M | -15.80M | -15.80M | -16.89M | -17.98M |
| Income Before Tax | -16.75M | -16.68M | -16.61M | -16.92M | -17.24M |
| Income Tax Expenses | -4.88M | -3.88M | -2.88M | -1.21M | 449.00K |
| Earnings from Continuing Operations | -11.86 | -12.80 | -13.73 | -15.71 | -17.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.86M | -12.80M | -13.73M | -15.71M | -17.69M |
| EBIT | -15.79M | -15.80M | -15.80M | -16.89M | -17.98M |
| EBITDA | -15.78M | -15.79M | -15.79M | -16.88M | -17.98M |
| EPS Basic | -0.11 | -0.12 | -0.13 | -0.15 | -0.17 |
| Normalized Basic EPS | -0.09 | -0.09 | -0.09 | -0.10 | -0.10 |
| EPS Diluted | -0.11 | -0.12 | -0.13 | -0.15 | -0.17 |
| Normalized Diluted EPS | -0.09 | -0.09 | -0.09 | -0.10 | -0.10 |
| Average Basic Shares Outstanding | 426.69M | 419.11M | 411.54M | 410.71M | 409.88M |
| Average Diluted Shares Outstanding | 426.69M | 419.11M | 411.54M | 410.71M | 409.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |